Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by HCallahann44on Aug 11, 2020 9:45am

212 Views

Post# 31391972

RE:Presser

they better do something...this year of "many catalysts" is half over...and this thing is circling the drain with top corporate insiders storming the exits...forget all the double talk and rosey promises...these insiders bailing out tells me we are nowhere near an upward inflection point...I was a fool to get suckered by this story...but I guess there are 20 years of fools who preceded me

Bullboard Posts

Changing Europe’s dependency on HREE from China